Targeted therapy and maintenance in myeloma

被引:0
作者
Mateos, Maria-Victoria [1 ]
Gonzalez-Calle, Veronica [1 ]
机构
[1] Univ Hosp Salamanca, Inst Biosanitario Salamanca IBSAL, Hematol Dept, Paseo San Vicente 58-182, Salamanca 37007, Spain
关键词
maintenance; multiple myeloma; targeted therapy; minimal residual disease; tolerability; MINIMAL RESIDUAL DISEASE; DIAGNOSED MULTIPLE-MYELOMA; STEM-CELL TRANSPLANTATION; ELDERLY-PATIENTS; LENALIDOMIDE TREATMENT; RANDOMIZED TRIALS; PLUS THALIDOMIDE; PHASE-III; PREDNISONE; MELPHALAN;
D O I
10.1093/bmb/ldx013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Maintenance therapy aims to extend progression-free survival (PFS) and overall survival (OS), but the convenience of administration, tolerability and toxicity are essentials. Source of data: A search was conducted to identify published literature and clinical studies about maintenance for multiple myeloma using PubMed and ClinicalTrials. gov. Areas of agreement: There are different drug classes able to ensure durable responses previously achieved after induction followed or not by transplant, translating into a significant benefit in PFS and OS. Areas of controversy: It is not well established the optimal maintenance approach, what the ideal duration of maintenance is, and whether all patients have to receive maintenance therapy. Growing points: To define the role of risk factors and minimal residual disease monitoring for tailored maintenance. Areas timely for developing research: The development of new therapies and monitoring strategies able to individualize the maintenance to prevent both under and overtreatment.
引用
收藏
页码:163 / 177
页数:15
相关论文
共 44 条
  • [1] [Anonymous], 2016, LANCET
  • [2] [Anonymous], 2015, BLOOD
  • [3] ATTAL M, 2016, J CLIN ONCOL S, V34
  • [4] Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
    Attal, Michel
    Harousseau, Jean-Luc
    Leyvraz, Serge
    Doyen, Chantal
    Hulin, Cyrille
    Benboubker, Lofti
    Agha, Ibrahim Yakoub
    Bourhis, Jean-Henri
    Garderet, Laurent
    Pegourie, Brigitte
    Dumontet, Charles
    Renaud, Marc
    Voillat, Laurent
    Berthou, Christian
    Marit, Gerald
    Monconduit, Mathieu
    Caillot, Denis
    Grobois, Bernard
    Avet-Loiseau, Herve
    Moreau, Philippe
    Facon, Thierry
    [J]. BLOOD, 2006, 108 (10) : 3289 - 3294
  • [5] Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
    Attal, Michel
    Lauwers-Cances, Valerie
    Marit, Gerald
    Caillot, Denis
    Moreau, Philippe
    Facon, Thierry
    Stoppa, Anne Marie
    Hulin, Cyrille
    Benboubker, Lofti
    Garderet, Laurent
    Decaux, Olivier
    Leyvraz, Serge
    Vekemans, Marie-Christiane
    Voillat, Laurent
    Michallet, Mauricette
    Pegourie, Brigitte
    Dumontet, Charles
    Roussel, Murielle
    Leleu, Xavier
    Mathiot, Claire
    Payen, Catherine
    Avet-Loiseau, Herve
    Harousseau, Jean-Luc
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) : 1782 - 1791
  • [6] Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Barlogie, B
    Tricot, G
    Anaissie, E
    Shaughnessy, J
    Rasmussen, E
    van Rhee, F
    Fassas, A
    Zangari, M
    Hollmig, K
    Pineda-Roman, M
    Lee, C
    Talamo, G
    Thertulien, R
    Kiwan, E
    Krishna, S
    Fox, M
    Crowley, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) : 1021 - 1030
  • [7] Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
    Barlogie, Bart
    Pineda-Roman, Mauricio
    Van Rhee, Frits
    Haessler, Jeff
    Anaissie, Elias
    Hollmig, Klaus
    Alsayed, Yazan
    Waheed, Sarah
    Petty, Nathan
    Epstein, Joshua
    Shaughnessy, John D., Jr.
    Tricot, Guido
    Zangari, Maurizio
    Zeldis, Jerome
    Barer, Sol
    Crowley, John
    [J]. BLOOD, 2008, 112 (08) : 3115 - 3121
  • [8] Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
    Benboubker, Lotfi
    Dimopoulos, Meletios A.
    Dispenzieri, Angela
    Catalano, John
    Belch, Andrew R.
    Cavo, Michele
    Pinto, Antonello
    Weisel, Katja
    Ludwig, Heinz
    Bahlis, Nizar
    Banos, Anne
    Tiab, Mourad
    Delforge, Michel
    Cavenagh, Jamie
    Geraldes, Catarina
    Lee, Je-Jung
    Chen, Christine
    Oriol, Albert
    de la Rubia, Javier
    Qiu, Lugui
    White, Darrell J.
    Binder, Daniel
    Anderson, Kenneth
    Fermand, Jean-Paul
    Moreau, Philippe
    Attal, Michel
    Knight, Robert
    Chen, Guang
    Van Oostendorp, Jason
    Jacques, Christian
    Ervin-Haynes, Annette
    Avet-Loiseau, Herve
    Hulin, Cyrille
    Facon, Thierry
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) : 906 - 917
  • [9] The impact of intra-clonal heterogeneity on the treatment of multiple myeloma
    Brioli, Annamaria
    Melchor, Lorenzo
    Cavo, Michele
    Morgan, Gareth J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (04) : 441 - 454
  • [10] Casassus P, 2001, BRIT J HAEMATOL, V113, P1020